46490 Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 

taper ensures higher damage threshold 

for the delivery waveguide in 

comparison to the conventional lens 

laser-to-fiber coupling. To improve the 

high-peak-power delivery capability of 

the proposed allow-hollow-waveguide 

DPIV illumination system, instead of a 

conventional solid-core fiber link, we 

have used a cyclic olefin polymer 

(COP)-coated hollow glass waveguide 

which is designed to minimize the 

waveguide attenuation losses at a 

typical DPIV laser wavelength of 532- 

nm. This waveguide provides a 

significantly higher laser power delivery 

capability and higher damage threshold. 

The all-hollow-waveguide DPIV laser 

delivery system offers essential 

advanced features over conventional 

bulk-optics-based delivery techniques in 

terms of formatting thin (0.5–1.0 mm), 

wide (10 mm or wider) and uniform 

laser illumination sheet; high-peakpower laser delivery without damaging 

effects (> 1 GW/cm2), flexibility, 

miniaturization, simplified alignment, 

immunity to external influence 

(including vibrations and angular laser 

beam drift), and safe and confined laser 

delivery. 

Applications 

2. Optics; Particle imaging: 

Velocimetry. 

Market 

4. Illumination, high peak laser 

powered delivery. 

Inventors 

6. Ilko K. Ilev, Ronald A. Robinson, 

Ronald W. Waynant (FDA). 

Publications 

1. IK Ilev et al., ‘‘Grazing-IncidenceBased Hollow Taper for Infrared Laserto-Fiber Coupling,’’ Applied Physics 

Letters, Vol. 74, 1999, pp. 2921–2923. 

2. IK Ilev et al., ‘‘Uncoated Hollow 

Taper as a Single Optical Funnel for 

Laser Delivery,’’ Review of Scientific 

Instruments, Vol. 70, 1999, pp. 3840–

3843. 

3. IK Ilev et al., ‘‘Ultraviolet Laser 

Delivery Using an Uncoated Hollow 

Taper,’’ IEEE Journal of Quantum 

Electronics, Vol. 36, 2000, pp. 944–948. 

4. IK Ilev et al., ‘‘Attenuation 

Measurement of Infrared Optical Fibers 

Using a Hollow-Taper-Based Coupling 

Method,’’ Applied Optics, Vol. 39, 2000, 

pp. 3192–3196. 

5. RA Robinson et al., ‘‘Design and 

Optimization of a Flexible High-Peak 

Power Laser-to-Fiber Coupled 

Illumination System Used in Digital 

Particle Image Velocimetry’’, Review of 

Scientific Instruments, Vol. 75, 2004, 

pp. 4856–4862. 

Patent Status 

8. U.S. Provisional Application No. 

60/730,866 filed 28 Oct 2005 (HHS 

Reference No. AE–015–2006/0–US–01). 

Licensing Status 

10. Available for non-exclusive or 

exclusive licensing. 

Licensing Contact 

Michael A. Shmilovich, Esq.; 301/ 

435–5019. shmilovm.@mail.nih.gov. 

<mailto:shmilovm@mail.nih.gov.> 

Collaborative Research Opportunity 

The Food and Drug Administration’s 

Center for Devices and Radiological 

Health is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact the inventors at 301/827–4685 

for more information. 

Dated: July 28, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer; Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–6873 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Model Th1 Clone Producing IFNgamma and IL–2 

Description of Technology 

Available for licensing is the A.E7 T 

cell clone, a model Th1 clone described 

in Matis et al., J Immunol. 1983 Apr 

130(4):1527–1535 [PubMed abs] and J 

Immunol. 1983 Sept 131(3):1049–1055 

[PubMed abs]. This clone has been 

further utilized as a model for studying 

T cell clonal anergy. 

Potential Applications of Technology 

2. Model Th1 clone capable of making 

IFN-gamma and IL–2 

4. Model T cell clone for studying T 

cell clonal anergy 

Inventors 

Ronald H. Schwartz et al. (NIAID). 

Louis A. Matis (NIAID). 

Dan L. Longo (NCI). 

Toby T. Hecht (NCI). 

Patent Status 

HHS Reference No. E–214–2006/0—

Research Tool. 

Licensing Status 

Available for non-exclusive licensing. 

Licensing Contact 

Susan Ano, Ph.D.; Phone: (301) 435–

5515; Email: anos@mail.nih.gov. 

Dated: July 31, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–6874 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditions 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 


jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 46491 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; telephone: 301/496–0220. 

A signed Confidential Disclosure 

Agreement will be required to receive 

copies of the patent applications. 

Complement Regulatory Gene Variants 

as Predictive Tests for Age-related 

Macular Degeneration (AMD) 

Description of Technology 

Age-related macular degeneration 

(AMD) is complex multigenic disorder 

that affects the central region of the 

retina (macula) and is the leading cause 

of legal blindness in developed 

countries. Age, lifestyle (e.g., smoking, 

diet) and genetic predisposition are 

major risk factors for AMD and 1.75 

million adults over 40 are affected by 

advanced AMD in the United States 

with a further 7 million considered to be 

at risk (defined by the presence of large 

retinal deposits or drusen, which are the 

hallmark of this disease). A variety of 

immune-associated molecules including 

immunoglobulins, complement 

components, activators and regulators, 

etc. are associated with drusen and 

evidence suggests that AMD, like other 

age-related diseases such as Alzheimer’s 

disease and atherosclerosis, involves a 

major inflammatory component. Several 

disease-susceptibility genes have been 

identified in family studies of macular 

degeneration and in patient cohorts by 

several groups including NIH 

researchers and their collaborators, and 

variants in the factor H gene (CFH)), a 

major inhibitor of the alternative 

complement pathway, have been 

associated with the risk for developing 

AMD. 

NIH researchers and their 

collaborators have now extended this 

work to two other regulatory genes of 

this pathway, Factor B (BF) and 

complement component 2 (C2). These 

genes were screened for genetic 

variation in two independent cohorts 

comprised of ~900 AMD cases and 

~400 matched controls. Haplotype 

analyses revealed a significant common 

risk haplotype (H1) and two protective 

haplotypes (H7 and H10). Combined 

analysis of the C2/BF haplotypes and 

CFH variants shows that variation in the 

two loci can predict the clinical 

outcome in 74% of the cases and 56% 

of the controls (Nature Genetics (2006) 

38, 458). This suggests that these 

variants can be used as predictive 

genetic tests in combination with other 

potential risk factors. 

Available for licensing are methods 

for identifying a subject at increased risk 

for developing AMD by determining the 

presence of protective genotypes at 

either the BF/C2 locus and at the CFH 

locus. Microarrays and kits are also 

provided. The complex and polygenic 

nature of AMD suggests that the 

protective and risk haplotypes claimed 

here can be of great value not only to 

companies targeting Macular 

Degeneration but perhaps more broadly 

to those involved in complementmediated inflammatory disorders. 

Inventors 

Michael Dean (NCI), Bert Gold (NCI) 

et al. 

Patent Status 

U.S. Provisional Patent Application 

No. 60/772,989, filed 13 February 2006 

(HHS Reference No. E–042–2006/0–US–

01). 

Licensing Status 

Available for non-exclusive or 

exclusive licensing. 

Licensing Contract 

Susan Carson, D.Phil.; 301–435–5020; 

mail to: carsonsu@mail.nih.gov. 

Collaborative Research Opportunity 

The NCI Laboratory of Genomic 

Diversity is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize functional or genetic 

tests on complement genes and proteins. 

Please contact Kathleen Higinbotham at 

301–846–5465 for more information. 

Dated: July 28, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–6879 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Licensing Opportunity 

From the National Institutes of Health 

Target-Specific Activatable Optical 

Probes for In Vivo Imaging 

Description of Technology 

Available for licensing and 

commercial development is an optical 

imaging method capable of detecting 

living cancer cells in vivo. The method 

increases sensitivity and reduces the 

background signal to extremely low 

levels. In contrast to conventional 

fluorescent imaging, the strategy 

activates the probe after it binds to and 

is internalized within cancer cells. 

Using antibodies, reagent-receptor 

systems, or cytokines to target the agent 

to the cancer, the agent is internalized 

by the normal cellular process of 

endocytosis which in turn, leads to 

molecular changes within the probe 

itself; fluorophores are activated only in 

the living targeted cells. 

An activatable fluorophore is one that 

is normally self-quenched by 

attachment to a peptide backbone but 

which can be activated by specific 

proteases which degrade the peptide 

resulting in ‘‘de-quenching.’’ For 

example, self-quenching avidinrhodaminex, which has affinity for 

lectin on cancer cells, is activated after 

endocytosis and degradation within the 

lysosome. Cellular internalization of 

receptor-ligand pairs with subsequent 

activation of fluorescence via ‘‘dequenching’’ provides a generalizable 

and highly sensitive method of 

detecting cancer microfoci in vivo and 

has practical implications for assisting 

surgical and endoscopic procedures. 

Application(s) 

2. Optical detection of tumor cells and 

metastatic nodules 

4. Photodynamic treatment of tumors 


jlentini on PROD1PC65 with NOTICES